The European Center for Disease Prevention and Control said the number of unusual pediatric hepatitis cases reached 450, double the number reported two weeks earlier.
U.S. health officials on May 6 said they are investigating 109 cases of severe hepatitis of unknown origin in children, including five reported deaths, updating a nationwide alert issued in April for doctors to be on the lookout for such cases of the liver disease.
The Covid-19 vaccine of AstraZeneca Plc and Oxford University works well as a third booster dose, stepping up antibodies to the coronavirus spike protein among participants in a study, the Financial Times said on May 19.
AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Ohio-based startup Forge Biologics closed a $40 million Series A financing round that will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.
Early data released from trials of three potential coronavirus vaccines, including a closely watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight Covid-19 without serious side effects.
A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.
Emergent BioSolutions entered a five-year manufacturing services deal with Janssen Pharmaceutical to manufacture Johnson & Johnson’s Ad26.COV2-S COVID-19 vaccine.
PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
